التفاصيل البيبلوغرافية
| العنوان: |
Treatment costs associated with commonly used branded antibiotics for the management of acute sinusitis, chronic bronchitis and pneumonia. |
| المؤلفون: |
Barron JJ, Gronchulski WD, Merchant S, Spooner JJ, Waugh WJ, Keating KN |
| المصدر: |
Journal of Applied Research; Winter2004, Vol. 4 Issue 1, p24-36, 13p |
| مستخلص: |
Objective: The purpose of this study was to determine the incidence of treatment failure and associated healthcare costs for outpatient management of community-acquired pneumonia, acute sinusitis, or chronic bronchitis in patients receiving the most commonly prescribed branded antibiotics.Methods: This was a retrospective analysis of pharmacy and medical claims. Members aged 18 years or older having an outpatient visit with a diagnosis of community-acquired pneumonia, acute sinusitis, or chronic bronchitis, and subsequent antibiotic prescription within 5 days were identified. Treatment failure was defined as a second antibiotic prescription, hospitalization, or emergency room visit for a respiratory infection within 30 days after the episode start. A multivariable regression model was used to compare total healthcare costs for moxifloxacin versus other antibiotics.Results: There were 45,231 patients who met the study criteria; these patients had 48,251 unique episodes of treated respiratory infections. Failure rates ranged from 15.9% to 24.1% for community-acquired pneumonia, 13.4% to 16.0% for acute sinusitis, and 14.7% to 28.5% for chronic bronchitis. Failure rates did not differ significantly between moxifloxacin and the other antibiotics for any of the diagnoses. The multivariable regression model revealed higher healthcare costs (rate ratio; 95% confidence interval) for communityacquired pneumonia for amoxicillin/clavulanate (1.41;1.03-1.93), levofloxacin (1.29;1.03-1.63) and ciprofloxacin (1.55;1.01-2.39) compared to moxifloxacin. For chronic bronchitis, cefuroxime (2.15; 1.06-4.36), gatifloxacin (1.60; 1.08-2.39), and clarithromycin (1.57;1.07-2.29) had higher costs compared to moxifloxacin. No significant differences in healthcare costs existed in the treatment of acute sinusitis.Conclusions: Although differences in failure rates between moxifloxacin and other antibiotics were not significant, analysis of total healthcare costs revealed that a number of antibiotics had higher adjusted total healthcare costs compared to moxifloxacin to treat a given episode. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Applied Research is the property of Therapeutic Solutions LLC and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
